Ceftiofur is an extended-spectrum cephalosporin approved in many countries worldwide for treatment of bovine respiratory disease (BRD), as well as respiratory disease of other animals. Ceftiofur has demonstrated excellent in vitro activity against bacteria of importance in BRD: Mannheimia spp., Pasteurella multocida, andHaemophilus somnus. Spectinomycin is an aminocyclitol antimicrobial agent. Spectinomycin sulfate was recently approved in the United States for treatment of BRD caused by P. multocida, Mannheimia spp., and H. somnus; approvals are currently pending in other countries. To determine the in vitro activity of ceftiofur and spectinomycin against recent BRD pathogens from France, The Netherlands and Germany, minimum inhibitory concentrations (MIC) were determined.